SOUTH SAN FRANCISCO, Calif., June 1, 2021 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced the closing of its first public offering of 11,500,000 shares of common stock , including the full exercise of the insurers’ option to purchase up to 1,500,000 additional shares of common stock, at a public offering price of $16.00 per share. All shares were offered by Day One. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering costs payable on day one, were $184.0 million. The shares traded on the Nasdaq Global Select Market on May 27, 2021, under the ticker symbol “DAWN.”
JP Morgan, Cowen and Piper Sandler acted as joint bookrunning managers for the offering. Wedbush PacGrow acted as lead manager for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission and became effective on May 26, 2021. The offering was made by way of a prospectus only. A copy of the final prospectus, if available, may be obtained from JP Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by email at firstname.lastname@example.org; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by phone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus Department, by phone at (800) 747-3924 or by email at email@example.com.
This press release does not constitute an offer to sell or a solicitation of an offer to purchase, nor will there be any sale of these securities in any state or other jurisdiction where such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About Day One Biopharmaceuticals, Inc.
Day One is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Day One was founded to address a critical unmet need: children with cancer are being left behind in a revolution in cancer drug development. Day One’s name is inspired by the ‘The Day One Talk’1 doctors have with patients and their families about an initial cancer diagnosis and treatment plan. Day one aims to rethink cancer drug development and redefine what is possible for all people with cancer – regardless of age – from day one.
Day One partners with leading clinical oncologists, families and scientists to identify, acquire and develop key emerging cancer treatments. The company’s lead product candidate, DAY101, is an oral, brain-penetrating, highly selective type II pan-RAF kinase inhibitor and is being evaluated in a pivotal Phase 2 clinical trial (FIREFLY-1) in children, adolescents and young adults. patients with recurrent or progressive low-grade glioma (pLGG). The company’s pipeline also includes the investigational drug pimasertib, a clinical-stage oral, highly selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK). Day One is based in South San Francisco.
1Jennifer W. Mack and Holcombe E. Grier; Journal of Clinical Oncology 2004 22:3, 563-566